Contents & References of The effect of 3 and 6 weeks of aerobic exercise on the growth and inflammatory factors of the liver following the induction of different doses of doxorubicin
List:
First chapter
1-1. Introduction. 2
1-2. State the problem. 3
1-3. The importance and necessity of research. 6
1-4. Objectives of the research: 9
1-4-1. general purpose 9
1-4-2. Special objectives. 9
1-5. Research hypotheses. 9
1-6. Definition of research words and terms. 10
Chapter Two
2-1. Introduction. 14
2-2. Theoretical foundations of research. 14
2-2-1. Anthracyclines and history. 14
2-2-2. Doxorubicin as a therapeutic agent. 17
2-2-3. Unintended toxicity of doxorubicin. 20
2-2-4. Unintended toxicity of doxorubicin in the liver. 23
2-2-5. Anatomy and physiology of liver tissue. 26
2-2-6. Cancer in the liver. 28
2-2-7. Mechanism of inflammation in cancer. 29
2-2-8. Structure and physiology of inflammatory factors. 31
2-2-8-1. Interleukin 10 (IL-10). 31
2-2-8-2. Interferon gamma (IFN?). 33
2-2-9. Growth apparatus. 35
2-2-10. IGF binding proteins. 41
2-3. Research background. 43
2-3-1. Studies of doxorubicin in non-sports and sports 43
Chapter 3
3-1. Introduction. 56
3-2. Research method. 56
3-3. Research subjects. 56
3-4. Research variables. 59
3-4-1. independent variables. 59
3-4-2. dependent variable. 59
3-5. Feeding and animal keeping environment: 59
3-6. Tools used in the research: 60
3-7. The training program of the subjects. 61
3-8. How to prepare and inject doxorubicin. 63
3-9. Tissue sampling and laboratory analysis. 64
3-10. Information analysis method. 65
Chapter Four
4-1. Introduction. 67
4-2. Descriptive data analysis. 67
4-2-1. Insulin-like factor (IGF-1). 67
4-2-2. IGF-1 binding protein-1 (IGFBP-1). 70
4-2-3. IGF-binding protein-3 (IGFBP-3). 73
4-2-4. Ratio of IGF-1 to IGFBP-3. 75
4-2-5. Interferon gamma. 78
4-2-6. Interleukin 10 (IL-10). 80
4-3. Testing research hypotheses. 82
4-3-1. Test of the first hypothesis. 83
4-3-2. Test of the second hypothesis. 85
4-3-3. Test of the third hypothesis. 86
4-3-4. The fourth hypothesis test. 88
4-3-5. Test of the fifth hypothesis. 90
4-3-6. Sixth hypothesis test. 91
Chapter Five
5-1. Introduction. 95
5-2. Summary of the research. 95
5-3. Discussion and review. 100
5-3-2. Investigation of IGFBP3. 105
5-3-3. Review of IL-10. 107
5-3-4. Investigating changes in INF-?. 109
5-4. conclusion 112
5-5. Research limitations. 113
5-6. Research proposals. 113
5-6-1. Suggestions arising from research. 113
5-6-2. Suggestions for future researchers. 114
Resources. 116
Appendix. 125
Appendix A. 125
Source:
Eddington and Edgerton, translated by Nikbakht, Hojjat A., (1380): "Biology of physical activity", organization for the study and compilation of humanities books of universities (Samt).
Ahmedin Jemal DVM.(2012) A Cancer Journal for Clinicians. American Cancer Society;(62):10-29.
Adam J. Chicco, Carole M. Schneider, and Reid Hayward(2005) Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol 289: R424–R431
Ana R. Lehenbauer Ludke, Abd Al-Rahman S. Al-Shudiefat, Sanjiv Dhingra, Davinder S. Jassal, and Pawan K. Singal(2009) A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity Can. J. Physiol. Pharmacol. 87: 756–763.
Ascensao A, Magalhaes J, Soares J, Ferreira R, Neuparth M, Marques F, Oliveira J, and Duarte J. (2005) Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int J Cardiol 100: 451–460.
Andrea Y. Arikawa, Mindy S. Kurzer, William Thomas, and Kathryn H. Schmitz. No effect of exercise on insulin-like growth factor (IGF)-1, insulin and glucose in young women participating in a 16-week randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2010; 19(11): 2987–2990.
Andrea Y. Arikawa, Mindy S.Kurzer, William Thomas, and Kathryn H. Schmitz. No effect of exercise on insulin-like growth factor (IGF)-1, insulin and glucose in young women participating in a 16-week randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2010; 19(11): 2987–2990.
Adams, G.; Stratford, I. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 231-238.
American Liver Foundation. The Progression of Liver Disease. 2013.
American Cancer Society. Adult Primary Liver Cancer Treatment. 2012.
Abbas A.B.; Lichtman A.H. "Ch.2 Innate Immunity". In Saunders (Elsevier). Basic Immunology. Functions and disorders of the immune system; (2009).
Anita G?lvez, José Miguel Eltit, Paula Ocaranza. IGF-1 Regulates Apoptosis of Cardiac Myocyte Induced by Osmotic-Stress. Chemical and Pharmaceutical Sciences.(2004);43-78.
Adelheid Soubry, Dora Il'yasova, Rebecca Sedjo, Frances Wang, Tim Byers, Clifford Rosen. Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps.(2011);26:126-198.
Ana S. Martins, Carlos Mackintosh, David Herrero Mart?n, Maria Campos, Teresa Hern?ndez, Jose-Luis Ord??ez and Enrique de Alava. Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor. Cancer Res. 2006 ;12: 35-58.
Arikawa AY, Kurzer MS, Thomas W, Schmitz KH. No effect of exercise on insulin-like growth factor-I, insulin, and glucose in young women participating in a 16-week randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2987-90.
A M M Haydon1, R J MacInnis2, D R English3, H Morris4, G G Giles3. Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Colorectal cancer. 2006;55:689-694.
Aline Bolpetti, Jo?o S Silva, Luisa L Villa and Ana Paula Lepique. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunology 2010, 11:27.
Bonfante, V; Bonadonna, G; Villani, F; Martini, A (1980). "Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia". Recent results in cancer research 74: 192–9
Breslow, N.; Ou, S.; Beckwith, M.; Haase, G.; Kalapurakal, J.; Ritchey, M.; Shamberger, R.; Thomas, P.; D'Angio, G.; Green, D. Doxorubicin for Favorable Histology, Stage II-III Wilms Tumor Results from the National Wilms Tumor Studies. Cancer, 2004,101, 1072-1080.
Box, V. The intercalation of DNA double helices with doxorubicin and nagalomycin. J. Mol. Graph Mod., 2007, 26, 14-19.
Begleiter, A.; Leith, M. Activity of quinine alkylating agents in quinine resistant cells. Cancer Res., 1990, 50, 2872-2876.
Bernardi, P.; Scorrano, L.; Colonna, R.; Petronilli, V.; Di Lisa, F. Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur. J. Biochem., 1999, 264, 687-701.
Bien, S.; Ritter, C.; Gratz, M.; Sperker, B.; Sonnemann, J.; Beck, J.; Kroemer, H. Nuclear factor-B mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol. Pharmacol., 2004, 65, 1092-1102.
Bien, S.; Ritter, C.; Gratz, M.; Sperker, B.; Sonnemann, J.; Beck, J.; Kroemer, H. Nuclear factor-B mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol. Pharmacol., 2004, 65, 1092-1102. Borsellino N, Crescimanno M, Flandina C, Leonardi V, Rausa L, D'Alessandro N. Antiproliferative and chemomodulatory effects of interferon-gamma on doxorubicin-sensitive and -resistant tumor cell lines. Anticancer Drugs. 1993 Apr;4(2):265-72.
Beech, D. J., Perer, E., Helms, J., Gratzer, A. & Deng, N.